Morgan Stanley (MS)

NYSEFinancialsFinancial - Capital MarketsSnapshot 2026-10-15

$180.54-0.86%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Morgan Stanley’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.1%

+10% or more+5%0%−5%−10% or less

13.70 → 13.71 EPS · FY ending Dec 31, 2027 · 17 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 17; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

5 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Quarterly dividend raised to $1.15 per share	The firm repurchases $20 billion in shares and raises dividends to $1.15 per share.	Intact	Dividend cut or fails to reach $1.15 per share in 2026-Q3	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS reaches $3.43 in 2026-Q1	A primary condition in Morgan Stanley's published investment case. The stated target is >= $3.43 per share.	Under Pressure	EPS falls below $3.0 in 2026-Q1	Diluted EPS: $3.46 per share FY2026-Q2; GAAP. Published target: >= $3.43 per share. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 4, 20263.46 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 84fc1f5d-ecf5-4dde-bc69-4738abb11550. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable interest rates and manageable inflation	A supporting condition in Morgan Stanley's published investment case. The stated target is Rates remain flat; inflation near 4.25% headline.	Under Pressure	Significant rate hikes or inflation spikes disrupting markets	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net revenues reach about $70.6 billion	A primary condition in Morgan Stanley's published investment case. The stated target is >= $70.6 billion.	Under Pressure	Revenue falls below $65 billion in 2025	Revenue: $15.902B FY2026-Q2; GAAP. Published target: >= $70.6 billion. Target period is not explicitly aligned with this observation. Source published Aug 4, 202615,902,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 84fc1f5d-ecf5-4dde-bc69-4738abb11550. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Execute $20 billion share repurchase program	The firm repurchases $20 billion in shares and raises dividends to $1.15 per share.	Intact	Buyback program is canceled or materially reduced	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Morgan Stanley repurchased $1.1B in 2025-Q3, $1.75B in 2026-Q1, and $1.5B in 2026-Q3, with a $20B multi-year share repurchase program reauthorized in 2026-Q2. The trajectory shows consistent execution and ongoing capital return commitment. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$13.71

$13.58 → $13.71 · observed estimates

FY2027 revenue$86.73B

$85.63B → $86.73B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$13.58	$85,630,284,365	16 / 12
2026-07-25	$13.59	$86,053,762,320	21 / 15
2026-07-26	$13.59	$86,053,762,320	21 / 15
2026-07-27	$13.64	$86,137,809,581	16 / 12
2026-07-28	$13.63	$86,285,095,650	21 / 15
2026-07-29	$13.63	$86,285,095,650	21 / 15
2026-07-30	$13.64	$86,137,809,581	16 / 12
2026-07-31	$13.64	$86,285,074,320	21 / 15
2026-08-01	$13.65	$86,169,072,739	16 / 12
2026-08-02	$13.64	$86,285,074,320	21 / 15
2026-08-03	$13.65	$86,169,072,739	16 / 12
2026-08-04	$13.65	$86,169,072,739	16 / 12
2026-08-05	$13.65	$86,501,620,030	21 / 15
2026-08-06	$13.65	$86,169,072,739	16 / 12
2026-08-07	$13.66	$86,339,998,302	16 / 12
2026-08-08	$13.65	$86,501,620,030	21 / 15
2026-08-09	$13.65	$86,501,620,030	21 / 15
2026-08-10	$13.66	$86,339,998,302	16 / 12
2026-08-12	$13.65	$86,501,620,030	21 / 15
2026-08-13	$13.65	$86,501,620,030	21 / 15
2026-08-14	$13.66	$86,339,998,302	16 / 12
2026-08-15	$13.66	$86,339,998,302	16 / 12
2026-08-16	$13.66	$86,339,998,302	16 / 12
2026-08-17	$13.66	$86,339,998,302	16 / 12
2026-08-18	$13.66	$86,339,998,302	16 / 12
2026-08-19	$13.66	$86,339,998,302	16 / 12
2026-08-20	$13.66	$86,339,998,302	16 / 12
2026-08-21	$13.66	$86,339,998,302	16 / 12
2026-08-22	$13.66	$86,339,998,302	16 / 12
2026-08-23	$13.66	$86,343,792,434	16 / 12
2026-08-24	$13.66	$86,343,792,434	16 / 12
2026-08-25	$13.66	$86,343,792,434	16 / 12
2026-08-26	$13.66	$86,343,792,434	16 / 12
2026-08-27	$13.66	$86,343,792,434	16 / 12
2026-08-28	$13.66	$86,343,792,434	16 / 12
2026-08-29	$13.66	$86,343,792,434	16 / 12
2026-08-30	$13.66	$86,343,792,434	16 / 12
2026-08-31	$13.66	$86,343,792,434	16 / 12
2026-09-01	$13.66	$86,343,792,434	16 / 12
2026-09-02	$13.66	$86,343,792,434	16 / 12
2026-09-03	$13.66	$86,343,792,434	16 / 12
2026-09-04	$13.66	$86,343,792,434	16 / 12
2026-09-05	$13.67	$86,343,792,434	16 / 12
2026-09-06	$13.67	$86,343,792,434	16 / 12
2026-09-07	$13.67	$86,343,792,434	16 / 12
2026-09-08	$13.67	$86,343,792,434	16 / 12
2026-09-09	$13.70	$86,466,808,171	16 / 12
2026-09-10	$13.70	$86,466,808,171	16 / 12
2026-09-11	$13.70	$86,466,808,171	16 / 12
2026-09-12	$13.70	$86,466,808,171	16 / 12
2026-09-13	$13.70	$86,466,808,171	16 / 12
2026-09-14	$13.70	$86,466,808,171	16 / 12
2026-09-15	$13.70	$86,466,808,171	16 / 12
2026-09-16	$13.70	$86,466,808,171	16 / 12
2026-09-17	$13.69	$86,451,922,908	16 / 12
2026-09-18	$13.69	$86,451,922,908	16 / 12
2026-09-19	$13.69	$86,451,922,908	16 / 12
2026-09-20	$13.69	$86,451,922,908	16 / 12
2026-09-21	$13.69	$86,451,922,908	16 / 12
2026-09-22	$13.69	$86,451,922,908	16 / 12
2026-09-23	$13.69	$86,451,922,908	16 / 12
2026-09-24	$13.69	$86,451,922,908	16 / 12
2026-09-25	$13.67	$86,344,922,908	16 / 12
2026-09-26	$13.67	$86,344,922,908	16 / 12
2026-09-27	$13.67	$86,344,922,908	16 / 12
2026-09-28	$13.72	$86,355,064,756	16 / 12
2026-09-29	$13.71	$86,355,064,756	16 / 12
2026-09-30	$13.71	$86,355,064,756	16 / 12
2026-10-01	$13.71	$86,359,979,317	16 / 12
2026-10-02	$13.70	$86,359,739,968	16 / 12
2026-10-03	$13.69	$86,373,476,810	16 / 12
2026-10-04	$13.69	$86,373,476,810	16 / 12
2026-10-05	$13.69	$86,373,476,810	16 / 12
2026-10-06	$13.70	$86,518,023,809	17 / 13
2026-10-07	$13.71	$86,579,078,042	17 / 14
2026-10-08	$13.67	$86,459,837,986	16 / 14
2026-10-09	$13.70	$86,629,162,303	17 / 14
2026-10-10	$13.70	$86,629,162,303	17 / 14
2026-10-11	$13.69	$86,581,741,250	17 / 14
2026-10-12	$13.69	$86,581,741,250	17 / 14
2026-10-13	$13.69	$86,581,741,250	17 / 14
2026-10-14	$13.69	$86,581,741,250	17 / 14
2026-10-15	$13.71	$86,727,244,547	17 / 14

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	14	1
2026-06-01	10	14	2
2026-07-01	11	13	2
2026-08-01	11	13	2
2026-09-01	11	13	2
2026-10-01	11	14	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 14 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades12 maintains

Recent actions · Sep 16–Oct 15 · 12 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 15 · prior Sep 25

$223.00 → $217.00-2.7%

RBC CapitalOct 15 · prior Jul 20

$243.00 → $195.00-19.8%

Morgan StanleyOct 14 · prior Jul 21

$215.00 → $200.00-7.0%

UBSOct 5 · prior Aug 3

$260.00 → $236.00-9.2%

$0$143.00$286.00

0 raises · 4 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Quarterly dividend raised to $1.15 per shareDirect metric needs a verified mapping
EPS reaches $3.43 in 2026-Q1Published status: Under Pressure
Stable interest rates and manageable inflationPublished status: Under Pressure
Net revenues reach about $70.6 billionPublished status: Under Pressure
Execute $20 billion share repurchase programDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-20.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Morgan Stanley outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a stable management team and a strong recent financial performance. However, the current state is complicated by sector headwinds and an expensive valuation compared to peers.

What's priced into Morgan Stanley

The market seems to have priced in a level of fragility due to weak execution quality, but the valuation remains justified. There is a slight expectations gap, indicating that the market may not fully reflect the company's recent strong performance.

What the fundamentals likely do

Fundamentals are likely to remain strong, supported by management's commitment to share repurchases and increasing dividends. However, there is a moderate risk due to potential misses in earnings, as industry peers have struggled recently.

What Morgan Stanley hinges on

The thesis hinges on several factors, including management's ability to maintain guidance, the performance of sector bellwethers, and the Federal Reserve's interest rate decisions. Any cuts in guidance or rate reductions could negatively impact the stock.